All In Biotech

Drug Trial Radar · NCT05206877

Topical Insulin for Glaucoma

Topical Insulin for Glaucoma and Optic Neuropathies

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Apr 1, 2022

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Stanford UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

Conditions

  • Glaucoma

Interventions

  • Insulin, 4 unitsDrug

    Topical insulin 100 U/ml, 1 drop per day

  • Insulin, 20 unitsDrug

    Topical insulin 500 U/ml, 1 drop per day

  • insulin, 4 units twice dailyDrug

    1 drop of low dose insulin twice daily.

  • insulin, 20 units twice dailyDrug

    1 drop of high dose insulin twice daily

  • insulin, 4 units three times dailyDrug

    1 drop of low dose insulin three times daily.

  • insulin, 20 units three times dailyDrug

    1 drop of high dose insulin three times daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Related Adverse EventsTime frame: During treatment period, difference from baseline to post-treatment up to 2 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Byers Eye Institute at Stanford University

    Palo Alto, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.